美托洛尔治疗冠心病心力衰竭临床分析

Clinical Analysis of Metoprolol in the Treatment of Heart Failure of Coronary Heart Disease

目的探究曲美他嗪结合美托洛尔对冠心病心力衰竭患者的疗效及对血浆BNP表达的影响。方法选取2018年10月-2019年2月期间我院收治的82例冠心病心力衰竭患者为研究对象,采用随机数字表法分组,随机分为观察组和对照组,观察组采取曲美他嗪结合美托洛尔的治疗方式,对照组患者则使用曲美他嗪。对比两组患者经治疗后BNP、LVESD、LVEDD、LVEF评分情况。结果治疗前,两组患者LVESD、LVEDD、LVEF差异不显著,不具有统计学意义,P>0.05;治疗后,观察组患者LVESD、LVEDD、LVEF水平均显著优于对照组,差异显著,具有统计学意义,P<0.05;治疗前,两组患者血浆BNP差异不显著,不具有统计学意义,P>0.05;治疗后,观察组患者血浆BNP水平均显著优于对照组,差异显著,具有统计学意义,P<0.05。结论曲美他嗪结合美托洛尔对冠心病心力衰竭患者疗效及血浆BNP表达有显著的治疗效果。

Objective To investigate the effect of trimetazidine combined with metoprolol on patients with coronary heart disease and the expression of plasma BNP.Eighty-two patients with coronary heart disease admitted to our hospital from October 2018 to February 2019 were selected.For the study subjects,they were randomly divided into observation group and control group by the random number table method.The observation group was treated with trimetazidine and metoprolol,while the control group was treated with trimetazidine.BNP,LVESD,LVEDD,and LVEF scores were compared between the two groups.Results Before treatment,the differences of LVESD,LVEDD and LVEF were not significant between the two groups,and there was no statistical significance,P>0.05.After treatment,the LVESD,LVEDD and LVEF levels in the observation group were significantly better than the control group,the difference was significant,P<0.05.Before treatment,the difference of plasma BNP between the two groups was not significant,P>0.05.After treatment,the plasma BNP level of the observation group was significantly better than the control group,the difference was significant,P<0.05.Conclusion Trimetazidine combined with metoprolol has a significant therapeutic effect on the efficacy and plasma BNP expression in patients with coronary heart disease and heart failure.